



Market Announcement

27 November 2020

Neurotech International Limited (ASX: NTI) – Suspension from Official Quotation

Description

The securities of Neurotech International Limited ('NTI') will be suspended from quotation immediately under Listing Rule 17.2, at the request of NTI, pending the release of an announcement regarding further results of the in-vitro cell studies of its cannabis strains.

Issued by

Jessica Coupe
Adviser, Listings Compliance (Perth)

Neurotech

27 November 2020

Sean Maloney
Senior Adviser, Listing Compliance (Perth)
Australian Securities Exchange
Level 40, Central Park
152 St Georges Terrace
PERTH WA 6000
BY EMAIL: sean.maloney@asx.com.au, tradinghaltspert@asx.com.au

Dear Mr Maloney

Request for Voluntary Suspension

Neurotech International Limited (ASX: NTI) ('Company') requests a voluntary suspension be placed on its securities.

The Company advises that:

- (a) it is seeking the voluntary suspension pending the release of further results of the in-vitro cell studies of its cannabis strains;
- (b) the Company wishes the voluntary suspension to remain in place until such time as it makes an announcement to the market in relation to the aforementioned results which it anticipates will be Monday 30th November 2020; and
- (c) the Company is not aware of any reason why its request for a voluntary suspension should not be granted.

Yours faithfully,



Winton Willesee

Director

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009

www.neurotechinternational.com